It has been determined that deamidation of peptide growth-hormonereleasing factor leading to aspartyl and iso-aspartyl forms reduces the bioactivity by 25- and 500-fold, respectively, as compared with the native peptide (36)
When considering IV therapy, it is essential to understand its key benefits, including swift access to the bloodstream and the ability to achieve higher concentrations of nutrients or medication
The peptide has a strong research base and a long clinical track record at our practice, but its used as part of a broader plan, not as a standalone fix
This leaves a stable, dry compound that is suitable for research applications
Humectant (INS 1518), Colour (INS 124, INS 110, INS 132)
The calculation is: Volume of Bacteriostatic Water (mL) = Peptide Vial Amount (mg) Desired Concentration (mg/mL)